• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

位置很重要:在利妥昔单抗治疗进展性多发性硬化症的临床试验中,来自不同中枢神经系统隔室的样本中存在高度差异的蛋白水平。

Location matters: highly divergent protein levels in samples from different CNS compartments in a clinical trial of rituximab for progressive MS.

机构信息

Department of Clinical Sciences, Umeå University, 901 85, Umeå, Sweden.

Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital, Stockholm, Sweden.

出版信息

Fluids Barriers CNS. 2020 Jul 29;17(1):49. doi: 10.1186/s12987-020-00205-4.

DOI:10.1186/s12987-020-00205-4
PMID:32727487
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7390226/
Abstract

BACKGROUND

The relationship between proteins in different CNS extracellular compartments is unknown. In this study the levels of selected proteins in three compartments in people with progressive multiple sclerosis (PMS) were compared.

METHODS

During an open label, phase 1b study on intraventricular administration of rituximab for PMS, samples were collected from the interstitial space (ISS) of the brain through microdialysis. Samples were also obtained from ventricular and lumbar cerebrospinal fluid (CSF). These samples were analyzed with a multiplexed proximity extension assay, measuring the levels of 180 proteins split equally between two panels, detecting proteins associated with immunology and neurology, respectively.

RESULTS

Considerable differences in concentrations were observed between the three analyzed compartments. Compared to ventricular CSF, ISS fluid contained statistically significant higher levels of 25 proteins (84% immunology panel and 16% neurology panel). Ventricular CSF contained significantly higher levels of 54 proteins (31% immunology panel and 69% neurology panel) compared to ISS fluid, and 17 proteins (76% immunology panel and 24% neurology panel) compared to lumbar CSF. Lumbar CSF showed significantly higher levels of 115 proteins (32% immunology panel and 68% neurology panel) compared to ventricular CSF. The three compartments displayed poor correlation with a median Spearman's rho of -0.1 (IQR 0.4) between ISS and ventricular CSF and 0.3 (IQR 0.4) between ventricular and lumbar CSF.

CONCLUSION

A substantial heterogeneity in the protein levels of samples obtained from different CNS compartments was seen. Therefore, data obtained from analysis of lumbar CSF should be interpreted with caution when making conclusions about pathophysiological processes in brain tissue.

摘要

背景

不同中枢神经系统细胞外隔室中蛋白质之间的关系尚不清楚。在本研究中,比较了进展性多发性硬化症(PMS)患者三个隔室中选定蛋白质的水平。

方法

在一项针对 PMS 患者脑室内给予利妥昔单抗的开放性、1b 期研究中,通过微透析从脑间质空间(ISS)采集样本。还从脑室和腰脊髓液(CSF)中采集样本。这些样本使用多重邻近延伸分析进行分析,该分析测量了 180 种蛋白质的水平,这些蛋白质平均分布在两个面板中,分别检测与免疫学和神经病学相关的蛋白质。

结果

在所分析的三个隔室之间观察到浓度存在相当大的差异。与脑室 CSF 相比,ISS 液中含有统计学上显著更高水平的 25 种蛋白质(免疫学面板 84%,神经病学面板 16%)。与 ISS 液相比,脑室 CSF 中含有统计学上更高水平的 54 种蛋白质(免疫学面板 31%,神经病学面板 69%),与腰 CSF 相比,含有 17 种蛋白质(免疫学面板 76%,神经病学面板 24%)。与脑室 CSF 相比,腰 CSF 显示统计学上更高水平的 115 种蛋白质(免疫学面板 32%,神经病学面板 68%)。三个隔室之间相关性较差,ISS 和脑室 CSF 之间的中位数 Spearman's rho 为-0.1(IQR 0.4),脑室和腰 CSF 之间为 0.3(IQR 0.4)。

结论

从不同中枢神经系统隔室获得的样本中蛋白质水平存在显著异质性。因此,在得出关于脑组织病理生理过程的结论时,应谨慎解释从腰 CSF 分析中获得的数据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/975d/7390226/65beeea54dec/12987_2020_205_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/975d/7390226/7796ab16ad68/12987_2020_205_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/975d/7390226/e6c0fabb511f/12987_2020_205_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/975d/7390226/b70b48e3c148/12987_2020_205_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/975d/7390226/02786c7792bc/12987_2020_205_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/975d/7390226/65beeea54dec/12987_2020_205_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/975d/7390226/7796ab16ad68/12987_2020_205_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/975d/7390226/e6c0fabb511f/12987_2020_205_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/975d/7390226/b70b48e3c148/12987_2020_205_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/975d/7390226/02786c7792bc/12987_2020_205_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/975d/7390226/65beeea54dec/12987_2020_205_Fig5_HTML.jpg

相似文献

1
Location matters: highly divergent protein levels in samples from different CNS compartments in a clinical trial of rituximab for progressive MS.位置很重要:在利妥昔单抗治疗进展性多发性硬化症的临床试验中,来自不同中枢神经系统隔室的样本中存在高度差异的蛋白水平。
Fluids Barriers CNS. 2020 Jul 29;17(1):49. doi: 10.1186/s12987-020-00205-4.
2
Trial of intrathecal rituximab in progressive multiple sclerosis patients with evidence of leptomeningeal contrast enhancement.鞘内利妥昔单抗治疗有软脑膜对比增强证据的进展性多发性硬化患者的试验。
Mult Scler Relat Disord. 2019 May;30:136-140. doi: 10.1016/j.msard.2019.02.013. Epub 2019 Feb 11.
3
Cerebrospinal fluid:serum glucose ratio in the ventricular and lumbar compartments: implications for clinical practice.脑脊髓液:脑室和腰池部位的血清葡萄糖比值:对临床实践的影响。
Eur J Neurol. 2018 Feb;25(2):373-379. doi: 10.1111/ene.13513. Epub 2017 Nov 28.
4
Intrathecal treatment trial of rituximab in progressive MS: An open-label phase 1b study.鞘内注射利妥昔单抗治疗进展性多发性硬化症的开放性 1b 期试验。
Neurology. 2018 Nov 13;91(20):e1893-e1901. doi: 10.1212/WNL.0000000000006500. Epub 2018 Oct 10.
5
Natalizumab in progressive MS: results of an open-label, phase 2A, proof-of-concept trial.那他珠单抗治疗进展型多发性硬化症:一项开放标签、2A期概念验证试验的结果
Neurology. 2014 Apr 29;82(17):1499-507. doi: 10.1212/WNL.0000000000000361. Epub 2014 Mar 28.
6
Comparison of plasma and cerebrospinal fluid neurofilament light in a multiple sclerosis trial.多发性硬化症试验中血浆和脑脊液神经丝轻链的比较。
Acta Neurol Scand. 2019 May;139(5):462-468. doi: 10.1111/ane.13078. Epub 2019 Mar 5.
7
The effects of intrathecal rituximab on biomarkers in multiple sclerosis.鞘内注射利妥昔单抗对多发性硬化症生物标志物的影响。
Mult Scler Relat Disord. 2016 Mar;6:49-53. doi: 10.1016/j.msard.2016.01.001. Epub 2016 Jan 19.
8
Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone.接受那他珠单抗或米托蒽醌治疗的多发性硬化症患者脑脊液中的可溶性触发受体表达于髓样细胞2(TREM-2)
Mult Scler. 2016 Oct;22(12):1587-1595. doi: 10.1177/1352458515624558. Epub 2016 Jan 11.
9
Neuroprotein dynamics in the cerebrospinal fluid: intraindividual concomitant ventricular and lumbar measurements.脑脊液中神经蛋白动力学:个体内同时进行的脑室和腰椎测量。
Eur Neurol. 2013;70(3-4):189-94. doi: 10.1159/000352032. Epub 2013 Aug 17.
10
Progressive multiple sclerosis cerebrospinal fluid induces inflammatory demyelination, axonal loss, and astrogliosis in mice.进展性多发性硬化症的脑脊液可诱导小鼠发生炎症性脱髓鞘、轴突丢失和星形胶质细胞增生。
Exp Neurol. 2014 Nov;261:620-32. doi: 10.1016/j.expneurol.2014.07.020. Epub 2014 Aug 8.

引用本文的文献

1
Comparative study on the sensitivity of lumbar puncture and external ventricular drainage cerebrospinal fluid in the diagnosis of central nervous system infections after craniotomy.开颅术后腰椎穿刺与脑室外引流脑脊液在中枢神经系统感染诊断中敏感性的比较研究
Front Neurol. 2025 Apr 15;16:1586394. doi: 10.3389/fneur.2025.1586394. eCollection 2025.
2
Intrathecal treatment of Anti-N-Methyl-D-Aspartate receptor encephalitis: a promising approach for refractory cases.鞘内注射治疗抗N-甲基-D-天冬氨酸受体脑炎:难治性病例的一种有前景的方法。
Neurol Sci. 2025 Mar 25. doi: 10.1007/s10072-025-08134-6.
3
Prostaglandins in the Inflamed Central Nervous System: Potential Therapeutic Targets.

本文引用的文献

1
Age-specific reference values for cerebrospinal fluid protein concentrations in children in southern China.中国南方儿童脑脊液蛋白浓度的年龄特异性参考值。
Medicine (Baltimore). 2019 Oct;98(41):e17500. doi: 10.1097/MD.0000000000017500.
2
Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.脑脊液神经丝轻链蛋白在神经病学中的诊断价值:一项系统评价和荟萃分析
JAMA Neurol. 2019 Sep 1;76(9):1035-1048. doi: 10.1001/jamaneurol.2019.1534.
3
Protein variability in cerebrospinal fluid and its possible implications for neurological protein biomarker research.
炎症性中枢神经系统中的前列腺素:潜在的治疗靶点。
Curr Drug Targets. 2024;25(13):885-908. doi: 10.2174/0113894501323980240815113851.
4
Regulation of brain fluid volumes and pressures: basic principles, intracranial hypertension, ventriculomegaly and hydrocephalus.脑液体积和压力的调节:基本原则、颅内高压、脑室扩大和脑积水。
Fluids Barriers CNS. 2024 Jul 17;21(1):57. doi: 10.1186/s12987-024-00532-w.
5
Negligible In Vitro Recovery of Macromolecules from Microdialysis Using 100 kDa Probes and Dextran in Perfusion Fluid.使用灌注液中的 100 kDa 探针和葡聚糖从微透析中回收大分子的体外回收率可忽略不计。
Neurochem Res. 2024 May;49(5):1322-1330. doi: 10.1007/s11064-024-04119-7. Epub 2024 Mar 13.
6
Detecting macromolecular differences of the CSF in low disability multiple sclerosis using quantitative MT MRI at 3T.使用3T定量磁化传递成像检测低残疾多发性硬化症患者脑脊液中的大分子差异。
Mult Scler J Exp Transl Clin. 2023 Nov 13;9(4):20552173231211396. doi: 10.1177/20552173231211396. eCollection 2023 Oct-Dec.
7
Cerebrospinal fluid cytokines after autologous haematopoietic stem cell transplantation and intrathecal rituximab treatment for multiple sclerosis.自体造血干细胞移植联合鞘内注射利妥昔单抗治疗多发性硬化后的脑脊液细胞因子
Brain Commun. 2023 Jan 20;5(1):fcad011. doi: 10.1093/braincomms/fcad011. eCollection 2023.
8
Differential proteomic profile of lumbar and ventricular cerebrospinal fluid.腰椎和脑室脑脊液的差异蛋白质组学图谱。
Fluids Barriers CNS. 2023 Jan 21;20(1):6. doi: 10.1186/s12987-022-00405-0.
9
The HeMoVal study protocol: a prospective international multicenter cohort study to validate cerebrospinal fluid hemoglobin as a monitoring biomarker for aneurysmal subarachnoid hemorrhage related secondary brain injury.HeMoVal 研究方案:一项前瞻性国际多中心队列研究,旨在验证脑脊液血红蛋白作为蛛网膜下腔出血相关继发性脑损伤的监测生物标志物。
BMC Neurol. 2022 Jul 18;22(1):267. doi: 10.1186/s12883-022-02789-w.
10
Association between single moderate to severe traumatic brain injury and long-term tauopathy in humans and preclinical animal models: a systematic narrative review of the literature.单次中度至重度创伤性脑损伤与人类和临床前动物模型中长期tau 病的关联:文献的系统叙述性综述。
Acta Neuropathol Commun. 2022 Jan 31;10(1):13. doi: 10.1186/s40478-022-01311-0.
脑脊液中的蛋白质变异性及其对神经蛋白生物标志物研究的可能影响。
PLoS One. 2018 Nov 29;13(11):e0206478. doi: 10.1371/journal.pone.0206478. eCollection 2018.
4
Intrathecal treatment trial of rituximab in progressive MS: An open-label phase 1b study.鞘内注射利妥昔单抗治疗进展性多发性硬化症的开放性 1b 期试验。
Neurology. 2018 Nov 13;91(20):e1893-e1901. doi: 10.1212/WNL.0000000000006500. Epub 2018 Oct 10.
5
Glymphatic MRI in idiopathic normal pressure hydrocephalus.特发性正常压力脑积水的脑淋巴系统磁共振成像
Brain. 2017 Oct 1;140(10):2691-2705. doi: 10.1093/brain/awx191.
6
CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.脑脊液和血液生物标志物在阿尔茨海默病诊断中的应用:系统评价和荟萃分析。
Lancet Neurol. 2016 Jun;15(7):673-684. doi: 10.1016/S1474-4422(16)00070-3. Epub 2016 Apr 8.
7
CSF, blood-brain barrier, and brain drug delivery.脑脊液、血脑屏障和脑部药物递送。
Expert Opin Drug Deliv. 2016 Jul;13(7):963-75. doi: 10.1517/17425247.2016.1171315. Epub 2016 Apr 11.
8
A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules.一个引流脑间质液和大分子的硬脑膜淋巴管系统。
J Exp Med. 2015 Jun 29;212(7):991-9. doi: 10.1084/jem.20142290. Epub 2015 Jun 15.
9
Structural and functional features of central nervous system lymphatic vessels.中枢神经系统淋巴管的结构和功能特征。
Nature. 2015 Jul 16;523(7560):337-41. doi: 10.1038/nature14432. Epub 2015 Jun 1.
10
The Glymphatic System: A Beginner's Guide.淋巴系统入门指南。
Neurochem Res. 2015 Dec;40(12):2583-99. doi: 10.1007/s11064-015-1581-6. Epub 2015 May 7.